No Data
List of conversion stocks (part 3) [Parabolic Cigna Corp conversion stocks list]
○ List of stocks that have shifted to Sell market Code Stock Name Closing Price SAR Tokyo Main Board <4433> Hitocom HD 925 977 <4481> Base 32253570 <4516> Nisshin Pharmaceutical 39474182 <4543> Terumo 26622803 <4547> Kissei Pharmaceutical 36203765 <4568> Daiichi Sankyo 34633752 <4617> China Coating 20922231 <4626> Taiyo HD
List of cloud breakout stocks (weekly) [Ichimoku Kinko Hyo - List of cloud breakout stocks]
○ List of stocks that broke through the clouds in the market Code Stock Name Closing Price Leading Span A Leading Span B Tokyo Stock Exchange Main Board <1879> Shin Nihon Ken 1499 1489.5 1407.5 <1928> Sekisui House 3390 3371.5 3322.5 <2353> Nichiju 205 195 201 <25935> Ito En No. 1
Iseki & Co Logs Extraordinary Losses in Year 2024
Iseki: Extraordinary Report
Iseki Agricultural --- For the fiscal year ending December 2024, recurring profits exceeded Financial Estimates, and an increase in revenue and profits is expected for the fiscal year ending December 2025.
Iseki & Co. Ltd. <6310> announced its consolidated financial results for the fiscal year ending December 2024 on the 14th. Revenue decreased by 0.9% year-on-year to 168.425 billion yen, operating profit decreased by 14.8% to 1.92 billion yen, ordinary profit decreased by 24.6% to 1.577 billion yen, and the net loss attributable to shareholders of the parent company was 3.022 billion yen (compared to a profit of 0.029 billion yen in the previous period). Due to increased foreign exchange gains, the ordinary profit is expected to increase by 57.8%, while other revenue and profit figures remained within the Financial Estimates.
Iseki Agricultural --- Progress report on "Project Z".
Iseki & Co. (6310) announced the progress of "Project Z" on the 14th, which was disclosed on July 18, 2024. The progress of each initiative is generally on track as planned. Among the fundamental structural reforms implemented in a short-term focused manner, production optimization "reorganization of production bases" and deepening domestic sales "building a foundation for growth strategy" are progressing as planned. Development optimization "improving product profit margins and streamlining development" and cost reduction are experiencing some delays, but development optimization is recovering through additional resources, and cost reduction is ongoing.